retatrutide clinical trial retatrutide mechanism Retatrutide—A Game Changer in Obesity Pharmacotherapy retatrutide mechanism retatrutide clinical trials

The drug was initially approved in 2017 for the treatment of type 2 diabetes under the brand name Ozempic

As a result, cagrilintide is increasingly used in studies of multi-pathway metabolic regulation, appetite biology, and peptide-based endocrine signaling networks [4][6]

But GLP-1 drugs, and the rapid weight loss they can produce, may accelerate that muscle loss

There is no established role for GLP-1 therapy in treating primary hormonal disorders such as thyroid disease, adrenal insufficiency, or pituitary dysfunctionthese conditions require specific hormone replacement or disease-directed therapy

Keep exploring our GLP-1 resources: